ArticleFrontiers in pediatrics2026
Association of caffeine citrate plus vitamin A/D drops with bronchopulmonary dysplasia and respiratory outcomes in preterm infants born at <32 weeks' gestation: a 72-h landmark retrospective cohort study.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this work is to examine whether the early addition of vitamin A/D drops to caffeine citrate was associated with bronchopulmonary dysplasia (BPD) and short-term respiratory outcomes in preterm infants born at <32 weeks' gestation. Methods: This single-center, 72-h landmark retrospective cohort study included 126 infants admitted to the hospital between October 2022 and November 2024 with a gestational age <32 weeks and birth weight ≤1.5 kg. Exposure was determined at 72 h as either caffeine alone or caffeine plus vitamin A/D drops. Complete-case analyses were performed. Among the 119 infants who survived to 36 weeks' postmenstrual age, BPD, longitudinal outcomes, and clinical course were evaluated. Multivariable regression and stabilized inverse probability of treatment weighting (IPTW) were applied. Results: BPD occurred in 20 of 55 survivors (36.4%) receiving caffeine alone and 11 of 64 (17.2%) receiving combination therapy. After adjustment for gestational age, birth weight, and grade III-IV respiratory distress syndrome, combination therapy was associated with a lower risk of BPD [adjusted odds ratio (aOR), 0.36; 95% confidence interval (CI), 0.14-0.90]. The composite outcome of death or BPD occurred in 25 of 60 infants (41.7%) in the caffeine group and 13 of 66 (19.7%) in the combination group (extended-model aOR, 0.33; 95% CI, 0.14-0.80); IPTW results were consistent. Combination therapy was also associated with more favorable changes in blood gas and inflammatory markers, along with shorter durations of respiratory support and hospitalization. No serious adverse event required permanent treatment discontinuation. Conclusion: Among infants who survived to 72 h, early initiation of vitamin A/D drops as an adjunct to caffeine was associated with lower risks of BPD and death or BPD, as well as more favorable short-term respiratory outcomes. Non-randomized treatment allocation, complete-case selection, and residual confounding preclude causal inference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.